Rezivertinib

SKU: orb1693561

Description

Rezivertinib

Research Area

Cardiovascular Research, Signal Transduction

Key Properties

• CAS Number: 1835667-12-3
• MW: 486.57
• Purity: 99.89%
• Formula: C₂₇H₃₀N₆O₃
• SMILES: O=C(C=C)NC1=CC(NC=2N=CC=C(N2)C3=CN(C=4C=CC=CC34)C)=C(OC)C=C1OCCN(C)C
• Target: EGFR
• Solubility: DMSO:100 mg/mL (205.52 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:4 mg/mL (8.22 mM)

Bioactivity

• Target IC50:
  A431 cells:>1000 nM (GI50)|HCC827 cells:6.8 nM (GI50)|NCI-H1975 cells:22 nM (GI50)|PC9 cells:13.3 nM (GI50)
• In Vivo:
  Rezivertinib administered orally for 14 days at 6.25-25 mg/kg/day demonstrated significant tumor regression. In addition, Rezivertinib administered orally at 50 mg/kg/day also showed anti-tumor effects, significantly improving the mean overall survival of the animals, which was prolonged from 13 to 28 days, a 115% improvement.
• In Vitro:
  Rezivertinib selectively inhibits cellular proliferation of EGFR mutations in cell lines: PC9 (GI50=13.3 nM), HCC827 (GI50=6.8 nM), NCI-H1975 (GI50=22 nM) and A431 (GI50>1000 nM).

Storage & Handling

• Storage: store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

EGFR, BPI7711, BPI-7711, Rezivertinib

Compound Identifiers

PubChem CID

118912975